In regards to what Pfeifer brings to the table, I would extend on your excellent analysis with a bit of speculation.
First: If the naltrexone is sequestered in the same polymer formulation each time, then the efficacy needs not be re-done each time. Ditto the HAL, just as fire puts out fire caused from wood or paper just the same, nal is well established to take care of all in the opioid class, so crushing all done. That leaves only the BE's--must show the formulation works, but then a very short path to submission.
Second: This is just the man to both oversee an assembly-type application process to the FDA, have connections with BP's, and assist on many levels. Kind of like the closer.
Thus--the strategy seems to be at a minimum, to get all the horses to starting gate as soon as possible. Line them up, and submission is 2.3 million each. The remaining to have BE's and applications--covered not only by current revenues, but new line of credit with LPC (if needed).
The only "risk" the company has left is with the first approval. This speaks to your point earlier about valuation--and here, beyond a multiple of revenues, any large premiums paid for a company are much more justifiable when they purchase a real product (including intellectual property) once the risk has been removed. True, they can get the company cheaper prior, but even with a large pop, the cost is still negligible to a BP--and if we do go to $1-2, the percentage premium for an acquisition would be that much less. Once the concept is proven, and company aligned many, all in high demand, for very credible submission, it's value jumps exponentially.
To the BP's with not only deep pockets, but also looking for an edge over their own competitors, this "generic" actually becomes a differentiated "flagship" which, with the blessings of the FDA, will allow for real inroads to the market share of other BP's. It's value is what they can do with it, not what we are restricted to. NH was playing coy when he stated all he wanted was a "small share of PFE's market share"...NH wants it all. And on top of all, this "generic" also enjoys the competitive advantage of essentially being it's own generic. If this becomes the opioid standard, how can one generic a generic?
Next to the NDA submission, this hiring was the next biggest news to hit the stock, yet slid by unnoticed. Most reading the wires just see an OTC company hired some new guy to their BOD without any further DD.
IMO, this new addition to the team signals the beginning of the end period of opportunity. Once we get to July (if not accepted sooner) the price to buy tons of shares on the cheap will be over. It will be interesting to see how NH plays this out--actually bringing all these to market, gain global approvals and expand markets next, go with a growth strategy, or opt to position for a really sweet buyout. I 100% agree on the genius of NH, and this last move of getting Pfiefer on the board is further confirmation. I'm lucky to have taken advantage of at .20 buying as it sat there for months...now the opportunity is .30...in 4 months this is going to change in a big way one way or another.
Doesn't seem to me Pfiefer would have jumped on something he thought to be a losing proposition. I would be interested in knowing if he was getting paid in cash or shares. Rock on N2K...great stuff. This is looking better and better.
Maz
"Beware of missing chances; otherwise it may be altogether too late some day" -- Franz Liszt
